N-acetyltyrosine

05/01/1986 - "Immune complexes used in these studies included EA-IgG, EA-IgM, tetanus-human anti-tetanus, and aggregated human IgG. There appeared to be specificity to the inhibition reaction since C4 by itself could inhibit C1 consumption by EA-IgM, whereas the presence of C3 was also required to control EA-IgG. Finally, N-acetyl-L-tyrosine was added to NHS at a final concentration of 30 mM. This nucleophile did not interact with native C3 or C4, nor did it directly activate C1. "

01/01/1981 - "However it was shown that all the compounds had slight or no adjuvant activity on the induction of delayed-type hypersensitivity to ABA-N-acetyl-L-tyrosine. "
04/01/1979 - "Synthetic 6-O-mycoloyl-N-acetylmuramyl-L-seryl-D-isoglutamine was active as an adjuvant for the induction of delayed-type hypersensitivity to m-[4-(4'-arsono-phenylazo)-phenyl]-N-acetyl-L-tyrosine in guinea pigs and for cell-mediated cytotoxicity in allogeneic mice. "
01/01/1976 - "It is also shown that these compounds have no adjuvant activity on the development of delayed type hypersensitivity to ABA-N-acetyltyrosine in guinea pigs. "
08/01/1988 - "All the multiprenylacetyl MDP derivatives, particularly TMD-232, showed potent adjuvant activity on the circulating antibody formation against bacterial alpha-amylase in mice, and induction of delayed-type hypersensitivity to monoazobenzenearsonate N-acetyl-L-tyrosine in guinea-pigs. "
07/01/1976 - "It was concluded that the minimal adjuvant-active subunit of cell wall peptidoglycan for the induction of delayed-type hypersensitivity to monoazobenzenearsonate-N-acetyl-L-tyrosine and for circulating-antibody formation to bacterial alpha-amylase and the thymus-independent antigen DNP-Ficoll was N-acetylmuramyldipeptide, MurNAc-L-Ala-D-isoGln. "

07/01/2004 - "N-acetyl tyrosyluria caused by parenteral or enteral administration of N-acetyl-L-tyrosine: differentiation from hereditary and acquired tyrosinemias."
01/01/1986 - "Increased excretion of N-acetylphenylalanine occurred in PKU, and in tyrosinemia both the latter compound and increased N-acetyltyrosine excretion were observed. "
01/01/2013 - "The patient showed increases in multiple plasma amino acids including tyrosine, phenylalanine and methionine, and hyper-excretions of 4-hydroxyphenyl-acetate, -pyruvate, and -lactate, as well as N-acetyltyrosine which could be seen in liver failure due to both tyrosinemia type I and non-metabolic conditions. "

11/10/1975 - "Delayed hypersensitivity to mono-azobenzene arsonate-N-acetyl-L-tyrosine. "
10/20/1975 - "Delayed hypersensitivity to mono-azobenzene-arsonate-N-acetyl-L-tyrosine. "
02/01/1966 - "Hapten-specific delayed hypersensitivity was produced by immunization of guinea pigs with arsanilic acid conjugated to N-acetyltyrosine or other small aromatic molecules. "

04/01/1995 - "The impact of hepatic dysfunction on the elimination and hydrolysis of three potential tyrosine sources for total parenteral nutrition, the dipeptides L-alanyl-L-tyrosine (Ala-Tyr) and glycyl-L-tyrosine (Gly-Tyr), and N-acetyl-L-tyrosine (Nac-Tyr) were evaluated in six patients with hepatic failure (five chronic, one acute) and seven healthy subjects. "
01/01/2013 - "The patient showed increases in multiple plasma amino acids including tyrosine, phenylalanine and methionine, and hyper-excretions of 4-hydroxyphenyl-acetate, -pyruvate, and -lactate, as well as N-acetyltyrosine which could be seen in liver failure due to both tyrosinemia type I and non-metabolic conditions. "